Breaking news

Exowatt’s Revolutionary Thermal Solar Power Promises Ultra-Low-Cost Energy

by THEFUTURE.TEAM

November 14, 2025

As the tech industry grapples with an emerging AI power crisis, Hannan Happi, co-founder and CEO of Exowatt, has set his sights on a bold objective: reducing electricity costs to one cent per kilowatt-hour. Drawing on decades-old concentrated solar power technology, Happi and his team have reimagined the conventional approach, refining every detail to optimize structural and maintenance costs while pushing the efficiency envelope.

A Modular Breakthrough In Thermal Energy

At the heart of Exowatt’s strategy is a deceptively simple system—a shipping container-sized unit crowned with a clear awning. Inside, a meticulously designed metal box fitted with sunlight-focusing lenses heats a specialized thermal brick. This process, augmented by a Stirling engine and an integrated generator, converts stored heat into mechanical energy, providing a reliable 24/7 power supply. The design, described by Happi as intentionally streamlined, enables rapid scaling: additional units can be deployed to meet increasing power needs.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Scaling Innovation With Strategic Investment

In pursuit of its ambitious one-cent-per-kilowatt-hour target, Exowatt recently secured an additional $50 million extension to its $70 million Series A round. The funding round, led by MVP Ventures and 8090 Industries, included participation from respected investors such as Atomic, BAM, Bay Bridge Ventures, DeepWork Capital, and others, along with previous backers like Andreessen Horowitz and Sam Altman. Happi noted that strong market momentum and heightened investor interest prompted the capital raise, positioning Exowatt for accelerated production and deployment.

Positioning Against Established Competitors

Exowatt is leveraging a mature, well-understood technology—often known as concentrated or thermal solar power—that has traditionally been outpaced by advancements in photovoltaic solar panels and lithium-ion batteries. However, by scaling a modular system known for its reliability, Exowatt aims to harness significant learning curve benefits. Happi highlights that while only a hundred or so solar thermal projects exist worldwide compared to the production of 1.5 billion solar panels annually, the streamlined scaling process offers a meaningful competitive edge.

Challenges And Market Alignment

Despite the promise, the Exowatt approach is not without its limitations. The physical footprint required for a large number of P3 units could restrict its viability in certain regions, and the solution is most effective in areas with abundant sunlight. Nonetheless, Happi is optimistic, noting a high degree of overlap between optimal deployment regions and new data center locations—a synergy that could redefine energy supply in this critical sector.

A Vision Beyond Conventional Energy

By repackaging a classic technology through modern manufacturing techniques and iterative design improvements, Exowatt is poised to disrupt the data center market and broader energy landscape. As the company scales production to reach its one-million-unit threshold per year, its innovative approach may serve as a blueprint for achieving previously unattainable levels of energy efficiency and cost reduction in the age of AI.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.